Biovet JSC (LTS:0III) EBIT: лв19.74 Mil (TTM As of Dec. 2016)


What is Biovet JSC EBIT?

Biovet JSC LTS:0III EBIT is лв19.74 Mil as of Dec. 2016. The stock has 1 warning sign investors should review.

Biovet JSC's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2016 was лв6.50 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2016 was лв19.74 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biovet JSC's annualized ROC % for the quarter that ended in Dec. 2016 was 9.78%. Biovet JSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2016 was 13.76%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Biovet JSC  (LTS:0III) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biovet JSC's annualized ROC % for the quarter that ended in Dec. 2016 is calculated as:

ROC % (Q: Dec. 2016 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2016 ) + Invested Capital (Q: Dec. 2016 ))/ count )
=30.588 * ( 1 - 23.46% )/( (238.567 + 240.297)/ 2 )
=23.4120552/239.432
=9.78 %

where

Invested Capital(Q: Sep. 2016 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=313.317 - 140.351 - ( 7.185 - max(0, 146.333 - 80.732+7.185))
=238.567

Invested Capital(Q: Dec. 2016 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=336.286 - 162.937 - ( 2.257 - max(0, 165.037 - 98.089+2.257))
=240.297

Note: The Operating Income data used here is four times the quarterly (Dec. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

Biovet JSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2016 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2016 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2016  Q: Dec. 2016
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=26.016/( ( (186.46 + max(-70.682, 0)) + (191.579 + max(-67.105, 0)) )/ 2 )
=26.016/( ( 186.46 + 191.579 )/ 2 )
=26.016/189.0195
=13.76 %

where Working Capital is:

Working Capital(Q: Sep. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.363 + 59.723 + 4.461) - (140.351 + 0 + 3.878)
=-70.682

Working Capital(Q: Dec. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.266 + 77.723 + 2.843) - (162.937 + 0 + 0)
=-67.105

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2016) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biovet JSC's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2016 )
=19.74/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biovet JSC EBIT Related Terms

Biovet JSC EBIT Historical Data

* Premium members only.

The historical data trend for Biovet JSC's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biovet JSC EBIT Chart

Biovet JSC Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EBIT
Get a 7-Day Free Trial 11.08 12.81 19.81 13.24 19.74

Biovet JSC Quarterly Data
Dec09 Dec10 Dec11 Dec12 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.76 2.61 8.73 1.90 6.50

LTS:0III vs ADMP, AGRX, BUDZ: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biovet JSC's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biovet JSC EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biovet JSC's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biovet JSC's EV-to-EBIT falls into.


Biovet JSC EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was лв19.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of лв19.74 Mil mean?
Biovet JSC (LTS:0III) has a EBIT of лв19.74 Mil as of Dec. 2016. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biovet JSC.
Is Biovet JSC's EBIT too high?
Biovet JSC's current EBIT is лв19.74 Mil.
How does Biovet JSC's EBIT compare to ADMP and AGRX?
Biovet JSC's EBIT of лв19.74 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biovet JSC. Biovet JSC's current EBIT is лв19.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biovet JSC stock overvalued right now?
Biovet JSC (LTS:0III) has a current EBIT of лв19.74 Mil. The current EBIT is лв19.74 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Biovet JSC (LTS:0III), the current EBIT is лв19.74 Mil as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biovet JSC Business Description

Biovet JSC manufactures & markets medicated and nutritional feed additives, enzymes, bulk active substances & pharmaceuticals for animal productivity & health. It offers intermediates, active ingredients and medicines for human pharmaceutical industry.